The FDA authorizes additional doses of the mRNA COVID-19 vaccine for some immunocompromised individuals


On 12 August 2021, the U.S. Food and Drug Administration (FDA) announced that it was amending the emergency use authorizations for both the Pfizer-BioNTech and Moderna COVID-19 vaccines to allow for the use of an additional dose in certain immunocompromised individuals, specifically, organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. Available data indicate that this group requires additional protection against COVID-19, as they are at increased risk of contracting and developing severe SARS-CoV-2 disease.

In addition, the FDA reported that the Advisory Committee on Immunization Practices, of the Centers for Disease Control and Prevention (CDC), will meet soon to discuss additional clinical recommendations regarding immunocompromised individuals. 


  • Share: